Jade Biosciences, Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
Jade Biosciences, Inc. (JBIO) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $2.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2025-03-27
- Jade Biosciences, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was $2.70M, a 157.77% increase from fiscal 2023.
- Jade Biosciences, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2023 was $1.05M.
- Jade Biosciences, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2022 was -$787.00K, a 784.35% decline from fiscal 2021.
- Jade Biosciences, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2021 was $115.00K, a 1050.00% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | $2.70M 10-K · filed 2025-03-27 |
| 2023-12-31 | $1.05M 10-K · filed 2025-03-27 |
| 2022-12-31 | -$787.00K 10-K · filed 2024-03-25 |
| 2021-12-31 | $115.00K 10-K · filed 2023-03-29 |
| 2020-12-31 | $10.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |